A venture capital firm founded in 1996 with offices in Silicon Valley, Beijing, Shanghai, and Tokyo has over $4.2B assets under management and has invested in over 400 companies. In 2019, the firm closed Fund IX at $780M, its largest fund to date. The firm invests mainly in early-stage technology companies (i.e. internet, SaaS, consumer-tech, etc.) with high disruptive potential and seeks to be the first institutional investor, but dedicates a small amount of capital (about 20% of the fund) to later-stage companies as well. Typically, first checks fall in the $2-5M range in Seed to Series A rounds, but the firm has made investments as small as $250K. Overall, the firm invests in over 20 companies per year across North America and Asia. In terms of healthtech specifically, the firm aims to make at least 1-2.

The firm is mainly interested in digital health opportunities and will not consider therapeutics or medical devices. The firm will stray away from anything that involves FDA regulatory approval. Previous investments of the firm include a Google Glass-powered remote scribe platform that improves the workflow of physicians, an AI engine that matches cancer patients with clinical trials, a wearable health tracker for healthy lifestyle management, etc. Companies do not need to be generating revenue prior to investment.

The firm invests in private companies with strong technology and can work with different kinds of management teams that are ideally devoted full-time to the company. The firm will almost always act as the lead investor and seek board representation, staying actively involved in their portfolio companies. The firm prefers to have a syndicate of co-investors invest alongside the firm, but this is not an absolute requirement.

If you are interested in more information about this investor and other investors tracked by LSN, please email resi@lifesciencenation.com.

A firm operates 80+ hospitals across Asia, the Middle East and Turkey has an innovation office that acts as a corporate VC arm, which has committed capital of $80 million to invest in the digital health space. The firm typically invests $5-10 million per opportunity, and will invest in companies worldwide that are interested in expanding into Asia.

The firm only invests in the digital health space. The firm is interested in many areas of digital health, diagnostics, and tech-enabled healthcare services, including wellness, digital therapeutics, AI, healthcare data, remote monitoring, chronic disease management, etc. The firm does not invest in biopharma or medtech.

The firm will invest globally, and is focused on startups that are interested in expanding into Asia.

If you are interested in more information about this investor and other investors tracked by LSN, please email resi@lifesciencenation.com.

A venture capital firm founded in 2019 and headquartered in Whitefish, Montana is seeking opportunities across all sectors of life sciences with a focus on biotechnologies, digital health, and infosec. The firm will engage in seed to series B rounds, but mostly looking to invest in series A. A typical allocation can range from 4 – 8 million USD. The firm will invest in companies that are based/headquartered in the US. The firm prefers to lead the investment round and will seek board seats when leading.

The firm is interested in novel technologies that address significant unmet needs in life sciences. The firm is most focused on biotechnologies and digital health but is open to considering all sectors in life sciences. Within the therapeutics sector, the firm is most interested in companies with a diversified pipeline in pre-clinical and clinical trial stages. The firm will consider opportunities in any indication, but has particular interest in oncology, immunology, and neurology. Within the digital health sector, the firm is interested in companies focused on value-based care models and technologies that incorporate machine learning and AI. The firm is also opened to considering medical devices and diagnostics companies of all stages of development. The firm is opportunistic in terms of subsectors and indications in these sectors.

The firm has no strict company or management team requirements, but prefers to work with companies led by founders with strong scientific and technical expertise. The firm does look to take an active role in helping the company to grow.

If you are interested in more information about this investor and other investors tracked by LSN, please email resi@lifesciencenation.com.

The family office investment fund is based in Taiwan. The fund focuses on healthcare, with investments including healthcare services as well as novel health technologies. The firm focuses on China, Taiwan and the US, and usually invests about $1 million per deal, but as the firm is a multi-stage investor, larger allocations are possible.

The fund is interested in medical devices, diagnostics and digital health, in addition to healthcare services. The firm is open to any indication area but has a particular interest in cardiology. The fund can make early stage investments but requires that the company at least have a working prototype/pilot product.

The fund primarily invests in companies that have operations in Asia but will also consider US-based companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The firm is a venture capital firm that was founded in 2019 and is headquartered in Western US. The firm is seeking opportunities across all sectors of life sciences with a focus on biotechnologies, digital health, and infosec. The firm will engage in seed to series B rounds, but mostly looking to invest in series A. A typical allocation can range from 4 – 8 million USD. The firm will invest in companies that are based/headquartered in the US. The firm prefers to lead the investment round and will seek board seats when leading.

The firm is interested in novel technologies that address significant unmet needs in life sciences. The firm is most focused on biotechnologies and digital health but is open to considering all sectors in life sciences. Within the therapeutics sector, the firm is most interested in companies with a diversified pipeline in pre-clinical and clinical trial stages. The firm will consider opportunities in any indication, but has particular interest in oncology, immunology, and neurology. Within the digital health sector, the firm is interested in companies focused on value-based care models and technologies that incorporate machine learning and AI. The firm is also opened to considering medical devices and diagnostics companies of all stages of development. The firm is opportunistic in terms of subsectors and indications in these sectors.

The firm has no strict company or management team requirements, but prefers to work with companies led by founders with strong scientific and technical expertise. The firm does look to take an active role in helping the company to grow.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

A hybrid family office operating in the USA can make investments ranging from approximately $500,000 to $100 million into companies and due to its funding structure has no requirements for holding period or capital structure. The firm makes investments in the forms of equity, controlling interest, in-licensing, MBO/LBO, growth capital and is also willing to co-invest. The firm is looking for companies located around the globe and makes around 5-15 investments in a given year.

The firm is looking for companies in sectors of Biotech Therapeutics and Diagnostics, Medtech, Digital Health, R&D Services, and Biotech Other. The firm is willing to consider all indications including orphan diseases, though they have some additional interest/experience is areas of Women’s Health, GI, Oncology and Cardiovascular, and Personalized Medicine including Proteomics and Genomics. The firm is most interested in companies that are in Phase II or later, nearing commercialization where the firm is capable of utilizing its operating company to scale up the company’s sales, marketing and distribution. That being said, the firm has made earlier stage investments in the past and is open to considering highly innovative and compelling early stage companies. The firm is also interested in companies developing consumables/reagents, service providers, food and nutraceuticals.

The firm looks to work with management teams with experience and grit and generally looks to take a board seat although it is not a requirement. The firm looks to leverage the use of its operating company to assist the company’s sales marketing and distribution efforts as well as providing assistance in operations management.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in the USA can invest anywhere from $4-30M, with $11M being the median initial check size. The firm invests in both seed and crossover rounds. While most of the current portfolio companies are USA-based, the firm has a global portfolio and is open to global investment opportunities.

The firm focuses on these 3 key areas: therapeutics, diagnostics, and R&D tools/services. The firm also considers digital health opportunities that tie in with their key areas, such as technologies enhancing R&D efficacy, drug development process, etc. The firm stirs away from medical devices (basically, all technologies that require FDA approval), including implantable devices. With regards to the firm’s main interest areas, The firm is most interested in seeing new approaches (i.e. cell & gene therapy, novel ways of manufacturing cell lines, etc). The firm will invest in both pre-clinical and clinical technologies.

The firm has no specific company or management team requirements and is open to working with management teams coming from varying levels of experience. The firm prefers to act as the lead investor, and has done so for almost all of their portfolio companies thus far. The firm is a very active, hands-on investor and will generally seek board representation.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.